瑞科生物-B(02179)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02179 瑞科生物-B

午间休市 08-20 09:00:00

5.000

+0.000

0.00%

最高5.000	最低5.000	成交量0.00
今开5.000	昨收5.000	日振幅0.00%
总市值31.30亿	流通市值22.90亿	总股本6.26亿
成交额0.00	换手率0.00%	流通股本4.58亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02179","market":"HK","secType":"STK","nameCN":"瑞科生物-B","latestPrice":5,"timestamp":1787187600015,"preClose":5,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":458092178,"shares":626000000,"eps":-1.3415764748325565,"marketStatus":"午间休市","change":0,"latestTime":"08-20 09:00:00","open":5,"high":5,"low":5,"amount":0,"amplitude":0,"askPrice":5.1,"askSize":9500,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-1.2587487098646335,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787202000000},"marketStatusCode":3,"adr":0,"listingDate":1648656000000,"exchange":"SEHK","adjPreClose":5,"openAndCloseTimeList":[[1787189400000,1787198400000],[1787202000000,1787212800000]],"volumeRatio":0,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02179","defaultTab":"news","newsList":[{"id":"1155056028","title":"瑞科生物-B（02179）公布董事会及三大专门委员会最新组成人员","url":"https://stock-news.laohu8.com/highlight/detail?id=1155056028","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1155056028?lang=zh_cn&edition=full","pubTime":"2026-08-19 22:16","pubTimestamp":1787148980,"startTime":"0","endTime":"0","summary":"2026年8月19日，江蘇瑞科生物技術股份有限公司公告披露，公司董事会由12名董事组成，其中包括：董事会主席兼非执行董事徐浩宇先生；执行董事刘勇博士、王静女士、魏其芳先生；非执行董事王如伟博士、张佳鑫博士、周宏斌博士、胡厚伟先生；独立非执行董事夏立军博士、梁国栋先生、GAO Feng教授、袁铭辉教授。公告显示，董事会同时设立审计委员会、薪酬与考核委员会及提名委员会三大专门委员会，各委员会成员及职务如下：","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02179"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102519531","title":"瑞科生物-B(02179)公布2026年中期业绩：收入0.05亿元 同比降逾99% 研发生物弃守亏损收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=1102519531","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102519531?lang=zh_cn&edition=full","pubTime":"2026-08-19 22:14","pubTimestamp":1787148843,"startTime":"0","endTime":"0","summary":"财联社讯 2026年8月19日，瑞科生物-B 披露截至2026年6月30日止六个月未经审核中期业绩。期内，公司实现收入47.00万元，较2025年同期的1,089.90万元减少99.57%。期内除税前亏损2.12亿元，同比减少37.70%；期内净亏损2.12亿元，同比减少37.82%。对应基本及摊薄每股亏损由上年同期的0.71元收窄至0.34元。行政开支4,089.6万元，同比下降14.40%；销售及分销开支234.4万元，同比增加209.31%，反映公司正搭建商业化销售团队。财务成本9,838万元，同比下降23.18%，源于部分债务融资偿还。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02179"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660426091","title":"瑞科生物-B(02179)公布中期业绩 母公司拥有人应占亏损约2.12亿元 同比收窄37.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660426091","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660426091?lang=zh_cn&edition=full","pubTime":"2026-08-19 22:08","pubTimestamp":1787148501,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞科生物-B(02179)公布2026年中期业绩，收入约4.7万元，同比减少99.57%;母公司拥有人应占亏损约2.12亿元，同比收窄37.82%;每股亏损0.34元。公告称，收入减少主要是由于于上期授予知识产权许可产生收入1080万元，本报告期内同类授权业务正在推进中，但尚未满足收入确认条件。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482271.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["02179","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191115788","title":"瑞科生物-B完成H股全流通　修订公司章程并更新股本结构","url":"https://stock-news.laohu8.com/highlight/detail?id=1191115788","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191115788?lang=zh_cn&edition=full","pubTime":"2026-08-17 21:41","pubTimestamp":1786974076,"startTime":"0","endTime":"0","summary":"2026年8月17日，江苏瑞科生物技术股份有限公司公告称，公司已就修订后的《公司章程》完成工商备案。此次修订源于公司H股全流通项目的落地实施。根据公告，公司已于2026年4月29日将合共141,953,489股未上市股份转换为H股，股份总数仍维持626,075,702股不变，但股本结构发生调整：。除上述条款外，《公司章程》其他内容保持不变。公司表示，修订后的完整章程已刊载于香港联交所披露易网站及公司官网。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02179"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179155489","title":"瑞科生物-B（02179）将于8月19日召开董事会审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1179155489","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1179155489?lang=zh_cn&edition=full","pubTime":"2026-08-07 21:01","pubTimestamp":1786107676,"startTime":"0","endTime":"0","summary":"瑞科生物-B（02179）8月7日公告称，公司董事会会议拟于2026年8月19日（星期三）举行，主要议程包括：1）审议并批准公司及其附属公司截至2026年6月30日止六个月的未经审计中期业绩；2）考虑派发中期股息（如有）。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02179"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155446928","title":"瑞科生物-B发布2026年7月股份变动月报表，股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1155446928","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1155446928?lang=zh_cn&edition=full","pubTime":"2026-08-03 12:12","pubTimestamp":1785730348,"startTime":"0","endTime":"0","summary":"2026年8月3日，瑞科生物-B披露了截至2026年7月31日的股份变动月报表。报告显示，当月公司已发行股份及注册股本均未发生变动，股本保持稳定。报告期内，公司未有进一步的股份期权、股权激励计划或其他股份变动事项披露。截至2026年7月31日，公司已确认满足香港联交所要求的公开持股量规定。公告由公司董事刘勇于2026年8月3日签署，并表示公司所有相关股份变动事项均已遵守香港联交所《上市规则》及适用法规的要求。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02179"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655354828","title":"瑞科生物-B(02179)发盈警 预期中期股东应占亏损2.01-2.22亿元 同比收窄约34.71%至40.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655354828","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655354828?lang=zh_cn&edition=full","pubTime":"2026-07-31 17:26","pubTimestamp":1785490009,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞科生物-B(02179)发布公告，预期截至2026年1月1日至2026年6月30日取得收入4-5.4万元人民币，同比减少约99.50%至99.63%;母公司拥有人应占亏损2.01-2.22亿元，同比收窄约34.71%至40.93%。报告期内亏损同比收窄，主要因本公司核心产品临床试验的主体工作及大规模投入阶段已按计划完成，随着部分项目重心转向注册核查及商业化准备，研发投入相应回落。与此同时，因上年同期本公司确认了一笔知识产权对外授权许可收入，报告期内，同类授权业务正在推进中但尚未满足收入确认条件，报告期内收入同比有所下降。整体而言，亏损呈收窄趋势，但仍有待进一步改善。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1474663.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02179","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131347046","title":"瑞科生物-B发布2026年中期业绩预告：亏损收窄34.71%—40.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=1131347046","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131347046?lang=zh_cn&edition=full","pubTime":"2026-07-31 17:25","pubTimestamp":1785489952,"startTime":"0","endTime":"0","summary":"公司预计报告期内继续录得亏损，但亏损幅度较上年同期显著收窄。根据公告，报告期内公司预计实现收入约4万—5.40万元，较上年同期的1,089.90万元下降约99.50%至99.63%；其他收入及收益预计为954.20万—1,054.60万元，同比减少约12.86%至21.16%。盈利能力方面，预计报告期除税前亏损为20,102.30万—22,218.30万元，较上年同期的33,957.30万元收窄约34.57%至40.80%；期内亏损及母公司拥有人应占亏损预计为20,123.00万—22,241.20万元，同期对比收窄约34.71%至40.93%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02179"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136731214","title":"瑞科生物-B预计2026年上半年亏损收窄34.7%至40.9%，净亏损约2.012亿至2.224亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1136731214","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136731214?lang=zh_cn&edition=full","pubTime":"2026-07-31 17:23","pubTimestamp":1785489820,"startTime":"0","endTime":"0","summary":"瑞科生物-B（02179.HK）近日发布业绩预告。公司预计，2026年上半年归属于股东的净亏损将大幅收窄，同比降幅介于34.7%至40.9%之间。据此测算，报告期内净亏损预计约为人民币2.012亿元至2.224亿元。这一数据表明，公司经营层面正逐步向好，亏损幅度呈现明显收敛态势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02179","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121477892","title":"瑞科生物-B披露带状疱疹及九价HPV疫苗最新研发进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1121477892","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121477892?lang=zh_cn&edition=full","pubTime":"2026-07-23 18:31","pubTimestamp":1784802662,"startTime":"0","endTime":"0","summary":"2026年7月23日，江蘇瑞科生物技術股份有限公司发布自愿公告，通报旗下带状疱疹疫苗REC610及九价HPV疫苗管线的最新进展。目前，REC610已完成药物临床试验现场检查及药品注册生产现场检查，后续将继续配合监管机构推进审评流程。REC610获受理及完成现场检查并不代表最终可以获批上市；HPV疫苗上市申报时间亦存在变动可能。截至公告披露日，董事会由董事会主席兼非执行董事徐浩宇先生及多名执行、非执行与独立非执行董事组成。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02179"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653749666","title":"瑞科生物-B(02179.HK)公布带状疱疹疫苗及九价HPV疫苗研发进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2653749666","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653749666?lang=zh_cn&edition=full","pubTime":"2026-07-23 18:27","pubTimestamp":1784802474,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02179","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158887164","title":"瑞科生物-B更新2026年6月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1158887164","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158887164?lang=zh_cn&edition=full","pubTime":"2026-07-02 16:56","pubTimestamp":1782982570,"startTime":"0","endTime":"0","summary":"2026年7月2日，瑞科生物-B发布2026年6月截至月报表。报告显示，截至2026年6月30日，公司注册股本总计人民币626,075,702元，包含内资股167,983,524股和H股458,092,178股，面值均为人民币1元，较上月结存数未发生变化。公告披露，报告期内，瑞科生物-B未进行任何新增发行、股份回购或注销，公司股本维持不变。同时，公告明确指出截至2026年6月底，公司已满足香港联合交易所有限公司相关上市规则中关于公众持股量的要求。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02179"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117744616","title":"瑞科生物-B公布2026年5月股份变动月报表，股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1117744616","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117744616?lang=zh_cn&edition=full","pubTime":"2026-06-01 12:10","pubTimestamp":1780287037,"startTime":"0","endTime":"0","summary":"江苏瑞科生物技术股份有限公司于2026年6月1日公布了截至2026年5月31日的证券变动月报表。报告显示，截止本月末，公司未出现新增发行、股份购回、注销及库藏股变动，股本结构保持稳定。报告同时指出，瑞科生物-B无任何股份期权计划及可换股票据变动，亦无其他股份相关协议或安排的变动。根据公告，瑞科生物-B已严格遵守香港联交所《上市规则》以及适用的法律及监管规定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02179"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120310362","title":"瑞科生物-B更新4月股份变动月报表，内资股与外资股转换为H股，总股本保持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1120310362","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120310362?lang=zh_cn&edition=full","pubTime":"2026-05-05 16:36","pubTimestamp":1777970211,"startTime":"0","endTime":"0","summary":"江苏瑞科生物技术股份有限公司于2026年5月5日发布了2026年4月的股份变动月报表，披露了报告期内各类股份以及注册股本的变动情况。报告期起止日为2026年4月1日至2026年4月30日。根据公告，报告期初内资股297,937,013股、非上市外资股12,000,000股及H股316,138,689股，合计626,075,702股。2026年4月29日，公司将129,953,489股内资股和12,000,000股非上市外资股转换为141,953,489股H股，从而使得本月末内资股数为167,983,524股，非上市外资股为0股，H股上升至458,092,178股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02179"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115951619","title":"瑞科生物-B：4月29日完成141,953,489股转换为H股，已发行股本相应变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1115951619","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115951619?lang=zh_cn&edition=full","pubTime":"2026-04-30 20:26","pubTimestamp":1777551999,"startTime":"0","endTime":"0","summary":"江蘇瑞科生物技術股份有限公司于2026年4月30日发布公告，指出公司已于4月29日将129,953,489股内资股与12,000,000股未上市外资股合计转换成141,953,489股H股。该转换数量占转换前已发行H股总数约44.9%。本次转换完成后，公司H股由316,138,689股增至458,092,178股；内资股由297,937,013股降至167,983,524股；未上市外资股则由12,000,000股降至0股，总发行股本仍维持626,075,702股不变。公司同时确认，本次股份变动已获得董事会正式授权，且符合所有适用的上市规则及相关法例。公告由董事刘勇签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"瑞科生物-B：4月29日完成141,953,489股转换为H股，已发行股本相应变动","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02179"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631328846","title":"瑞科生物-B(02179)：完成H股全流通","url":"https://stock-news.laohu8.com/highlight/detail?id=2631328846","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2631328846?lang=zh_cn&edition=full","pubTime":"2026-04-30 20:17","pubTimestamp":1777551457,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞科生物-B(02179)发布公告，已于2026年4月29日完成将合共1.42亿股未上市股份转换为H股，而转换后H股于2026年4月30日上午九时正于联交所开始上市。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1437467.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02179","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631579379","title":"瑞科生物-B(02179)股东将股票存入中国证券登记结算香港 存仓市值6.59亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2631579379","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2631579379?lang=zh_cn&edition=full","pubTime":"2026-04-30 08:20","pubTimestamp":1777508409,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，4月29日，瑞科生物-B(02179)股东将股票存入中国证券登记结算香港，存仓市值6.59亿港元，占比41.11%。此前瑞科生物-B发布截至2025年12月31日止年度业绩，收入人民币1272.6万元;股东应占亏损6.1亿元，同比扩大8.54%;每股亏损1.15元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1436934.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02179","BK1161","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153673563","title":"瑞科生物-B(02179)2025年首年实现疫苗商业化收入 高研发投入助力核心产品落地","url":"https://stock-news.laohu8.com/highlight/detail?id=1153673563","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153673563?lang=zh_cn&edition=full","pubTime":"2026-04-29 19:27","pubTimestamp":1777462064,"startTime":"0","endTime":"0","summary":"2025年度，瑞科生物-B录得首次产品商业化收入12.73亿元人民币，2024年度尚未产生收入。销售成本为1.49亿元，毛利为11.23亿元。同年其他收入及收益为2.07亿元，上年同期为0.62亿元。研发开支增至5.21亿元，上一年度为4.76亿元；销售及分销开支为1.56亿元，管理费用为0.91亿元，财务成本为0.03亿元。全年税前亏损6.08亿元，2024年度则为5.62亿元；最终年内亏损为6.10亿元，同比有所扩大。每股基本及摊薄亏损为1.15元人民币。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"瑞科生物-B(02179)2025年首年实现疫苗商业化收入 高研发投入助力核心产品落地","news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02179"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147177428","title":"瑞科生物-B2026年3月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1147177428","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1147177428?lang=zh_cn&edition=full","pubTime":"2026-04-01 17:32","pubTimestamp":1775035934,"startTime":"0","endTime":"0","summary":"江蘇瑞科生物技術股份有限公司于2026年4月1日发布2026年3月股份变动月报表。公告显示，截至2026年3月31日，各类股份无新增发行、购回、注销或库藏股变动，股本结构保持不变。江蘇瑞科生物技術股份有限公司报告期内的注册股本总额为人民币626,075,702元，具体包括297,937,013股内资股、12,000,000股非上市外资股及316,138,689股H股，面值均为每股人民币1元。公告同时披露，当月未发生期权、股权激励计划或可转换债券等相关变动。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02179"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622526011","title":"瑞科生物-B(02179)发布年度业绩 股东应占亏损6.1亿元 同比扩大8.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622526011","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2622526011?lang=zh_cn&edition=full","pubTime":"2026-03-25 07:10","pubTimestamp":1774393810,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞科生物-B 发布截至2025年12月31日止年度业绩，收入人民币1272.6万元;股东应占亏损6.1亿元，同比扩大8.54%;每股亏损1.15元。目前处于试生产阶段，匹配九价HPV疫苗临床研究进展以支持中国BLA申请。此外，公司已于2021年11月完成了基于CHO细胞表达系统的创新疫苗生产基地的建设，顺利取得由江苏省药监局颁发的疫苗生产许可证。该生产基地连续多年获得由欧盟质量授权人签发的符合性声明。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418411.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"瑞科生物-B(02179)发布年度业绩 股东应占亏损6.1亿元 同比扩大8.54%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02179"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0204},{"period":"1month","weight":-0.0079},{"period":"3month","weight":-0.0291},{"period":"6month","weight":0.1848},{"period":"1year","weight":-0.3631},{"period":"ytd","weight":0.25}],"compareEarnings":[{"period":"1week","weight":0.0022},{"period":"1month","weight":0.014},{"period":"3month","weight":0.0043},{"period":"6month","weight":-0.0348},{"period":"1year","weight":0.0148},{"period":"ytd","weight":-0.0053}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"江苏瑞科生物技术股份有限公司是一家从事疫苗研发的中国公司。该公司尚处于研发阶段。该公司的疫苗管线包括重组九价人乳头瘤病毒（HPV）、新佐剂重组九价HPV疫苗、重组二价（16/18）HPV疫苗、重组二价（6/11）HPV疫苗、新佐剂重组四价HPV疫苗、新佐剂重组带状疱疹病疫苗、新佐剂重组呼吸道合胞病毒疫苗、重组偏肺病毒疫苗、重组人巨细胞病毒疫苗、重组双组分新冠病毒疫苗、重组乙型肝炎病毒疫苗等。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.009257},{"month":2,"riseRate":0.25,"avgChangeRate":-0.058747},{"month":3,"riseRate":0.25,"avgChangeRate":-0.071963},{"month":4,"riseRate":0.4,"avgChangeRate":-0.012446},{"month":5,"riseRate":0.2,"avgChangeRate":-0.039249},{"month":6,"riseRate":0.2,"avgChangeRate":-0.012707},{"month":7,"riseRate":0.6,"avgChangeRate":0.000991},{"month":8,"riseRate":0.2,"avgChangeRate":-0.028343},{"month":9,"riseRate":0.25,"avgChangeRate":-0.012227},{"month":10,"riseRate":0.5,"avgChangeRate":0.027812},{"month":11,"riseRate":0,"avgChangeRate":-0.140794},{"month":12,"riseRate":0.75,"avgChangeRate":0.059254}],"exchange":"SEHK","name":"瑞科生物-B","nameEN":"RECBIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"瑞科生物-B(02179)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供瑞科生物-B(02179)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"瑞科生物-B,02179,瑞科生物-B股票,瑞科生物-B股票老虎,瑞科生物-B股票老虎国际,瑞科生物-B行情,瑞科生物-B股票行情,瑞科生物-B股价,瑞科生物-B股市,瑞科生物-B股票价格,瑞科生物-B股票交易,瑞科生物-B股票购买,瑞科生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"瑞科生物-B(02179)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供瑞科生物-B(02179)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}